MedTrace Logo

Influenza Vaccine in HIV

NCT00764998 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2017-04-28

No results posted yet for this study

Summary

The purposes of this research study are:

1. to see if there is a difference in the quantity of protective influenza antibodies produced by different doses of the Fluviral vaccine
2. to see if these different vaccine dosing schedules reduce flu-like illness and/or reduce laboratory documented influenza in HIV Infected adults.

Conditions

Interventions

BIOLOGICAL

Fluviral

Sponsors & Collaborators

  • Ontario HIV Treatment Network

    collaborator NETWORK

  • Public Health Agency of Canada (PHAC)

    collaborator OTHER_GOV

  • CIHR Canadian HIV Trials Network

    collaborator NETWORK

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Curtis Cooper, MD · OHRI

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-04-30
Completion
2009-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00764998 on ClinicalTrials.gov